同和药业(300636.SZ)：“富马酸伏诺拉生”原料药通过CDE审批

Core Viewpoint - The approval of "Fumaric Acid Vorinostat" active pharmaceutical ingredient (API) by the National Medical Products Administration (NMPA) indicates that the product meets China's drug review technical standards, allowing for its use in domestic formulations and enhancing the company's market presence both domestically and internationally [1] Group 1 - The company has received approval for its "Fumaric Acid Vorinostat" API from the CDE, which signifies compliance with relevant drug review standards in China [1] - This approval facilitates the company's expansion of product sales in the domestic market, contributing to a synchronized sales strategy in both domestic and international markets [1]